https://orcid.org/0000-0002-4868-8655
References
- Moll V , SchmidtPC , AmosCet.al Building regional anesthesia capacity in limited-resource settings: a pilot study evaluating a 4-week curriculum. Pain Manag.11(1), 29–37 (2021).
- Barros Dos Santos AO , Pintode Castro JB , LimaVP , da SilvaEB , deSouza Vale RG. Effects of physical exercise on low back pain and cortisol levels: a systematic review with meta-analysis of randomized controlled trials. Pain Manag.11(1), 49–57 (2021).
- Fayet M , HagenM. Pain characteristics and biomarkers in treatment approaches for osteoarthritis pain. Pain Manag.11(1), 59–73 (2021).
- Jain S , DeerT , SayedDet.al Minimally invasive lumbar decompression: a review of indications, techniques, efficacy and safety. Pain Manag.10(5), 331–348 (2020).
- Carinci AJ . Abuse-deterrent opioid analgesics: a guide for clinicians. Pain Manag.10(1), 55–62 (2020).
- Lash D , FrantzE , HurdleMFB. Ultrasound-guided cooled radiofrequency ablation of the genicular nerves: a technique paper. Pain Manag.10(3), 147–157 (2020).
- Hagen M , AlchinJ. Nonprescription drugs recommended in guidelines for common pain conditions. Pain Manag.10(2), 117–129 (2020).
- Dommerholt J . How have the views on myofascial pain and its treatment evolved in the past 20 years? From spray and stretch and injections to pain science, dry needling and fascial treatments. Pain Manag.10(2), 63–66 (2020).
- Kapural L , DeeringJP. A technological overview of cooled radiofrequency ablation and its effectiveness in the management of chronic knee pain. Pain Manag.10(3), 133–140 (2020).
- Ueda H . LPA receptor signaling as a therapeutic target for radical treatment of neuropathic pain and fibromyalgia. Pain Manag.10(1), 43–53 (2020).
- Hale M , GimbelJ , RauckR. Buprenorphine buccal film for chronic pain management. Pain Manag.10(4), 213–223 (2020).
- Javed S , HungJ , HuhBK. Impact of COVID-19 on chronic pain patients: a pain physician’s perspective. Pain Manag.10(5), 275–277 (2020).
- Chamberlain BH , RhinerM , SlatkinNE , StamblerN , IsraelRJ. Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer. Pain Manag.10(2), 73–84 (2020).